CG
INSY

Clinton Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Clinton Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-41,268
Closed -$380K – 1106
2016
Q4 		$380K Buy
41,268
+5,660
+16% +$63.9K 0.02% 645
2016
Q3 		$420K Buy
35,608
+18,240
+105% +$277K 0.02% 718
2016
Q2 		$225K Buy
+17,368
New +$253K 0.01% 807

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCP
Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Clinton Group's INSY Position: Q1 2017 in Review

Clinton Group sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 41,268 shares — an estimated $380K sold.

Clinton Group first reported a position in INSY in Q2 2016 and held it in 3 quarters. The position peaked at $420K in Q3 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

  • Clinton Group reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Clinton Group sold 41,268 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $380K.
  • Clinton Group first reported a position in Insys Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • Clinton Group's Insys Therapeutics, Inc. position peaked at $420K in Q3 2016.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Clinton Group's 13F filing for Q1 2017, filed 10 May 2017.